Systemic enzyme therapy in
the treatment of patients with myocardial infarction
Sledzevskaja U. K., Šumakov V. A.,
Bratus V. B., Babij A., Malinovskaja U. Z., Gavrilenko T. U., Terzov
A. U. Systemic enzyme therapy in the treatment of patients with
myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp.
43 – 44. 11 KR Czech translation of abstract
An immune statute of myocardial infarction (MI) patients is
significantly impaired. Preparation Wobenzym (Mucos Pharma, Germany)
shows a hypolipidemic and immunonormalizing effect, although its
application in the treatment of MI patients has not been studied
yet.
Two groups of patients with hyperlipidemia was administered with
Wobenzym : A (30 patients - 9 coated tablets for 10 days) B (13
patients - 9 coated tablets for 30 days). Patients received also
beta blockers, nitrates and aspirin. Controlled parameters were:
level of cholesterol, triglycerides, HDL, LDL and VLDL, coefficient
of atherogenity, lipoprotein level, activity – concentration of
diene conjugates, malonic acid dialdehyd, catalase activity.
Parameters of cell and humoral immunity –count of monocytes,
neutrophil granulocytes, phagocytary activity, level of
immunoglobulins, circulation immune complexes, antibodies against
infarcted myocardium, monoclonal antibodies – were followed, too.
In parallel with this clinical study an animal experiment was
conducted on two groups of rabbits with alimentary
hypercholesterolemia. First group of animals was control, second
group received Wobenzym in the daily dose 3 times higher than the
calculated dose per 1 kg of patients` body weight. Following
parameters were controlled during 2, 4, 6 and 8 weeks : level of
cholesterol in plasma, catalase activity, malonic acid dialdehyd,
coefficient of atherogenity, monocyte count.
Lowering of cholesterol level by 12% and lipoproteins by 16% was
observed in the patients from first group already after 10 days,
whereas patients from the second group showed decrease of
cholesterol level by 24% and lipoproteins by 31% within one month.
Level of malonic acid dialdehyde showed no changes for 10 days,
after one month was lowered.
These results support an antiatherogenic effect of Wobenzym which
can be seen after 10 days and antioxidant effect which can be seen
after long-term treatment.
In 2/3 of MI patients a lowered level of B and T lymphocytes and T
helpers and in 1/2 of patients lowering of T suppressors and natural
killers were found. Within one month the activity of cellular
imunity increased (normalization of T helper and natural killer
level). An elevated level of circulating immune complexes was found
in 80% of patients from both groups. Wobenzym therapy led to the
decrease of immune complex level by 38% in 88% of patients in second
group. Additionally, in all patients a higher titer of antibodies
against infarcted myocardium was observed. Antibody titer decreased
from 16 to 9 units in 50 % of patients in the second group after
Wobenzym therapy.
Antiatherogenic and hypolipidemic effect of Wobenzym was
experimentally verified. Treated animals showed cholesterol level
nearly two times lower than animals in control group. In treated
animals a decreased activity of oxidative reactions and increased
activity of antioxidative enzymes (seen in the level of malonic acid
dialdehyde) was observed. In the group of treated animals an
increased catalase activity was measured.
Obtained results support a therapeutical effect of Wobenzym in the
complex pathogenetic treatment of patients with myocardial
infarction.
Immunonormalizing, antiatherogenic and antioxidative effects of
Wobenzym influence the risk of reinfarction.
Investigation of the effect of long-term Wobenzym treatment on MI patients is planed.